Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA's Orphan Designation Backlog Plan Focuses On Efficiency, Not Staff

Executive Summary

No additional hiring is expected as US agency announces formal plan to return orphan review times to the original 90-day goal.


Related Content

US FDA's Orphan Drug Designation Reviews Often Don't Include Regulatory Histories, GAO Says
US FDA Appoints Another Orphan Products Development Office Head Amid Growth Expectations
What Is A Rare Pediatric Disease? US FDA's Orphan Products Office Hopes To Update Guidance On Definition
US FDA's Acting Orphan Products Development Director Has Gene Therapy Background
US FDA/NORD Partnership Will Further Increase Patient Involvement In Drug Development
FDA's Budget Flat In House Bill, But Path For 'Cures' Funding Cleared
US FDA 'Medical Innovation Development Plan' Outlined By Gottlieb
FDA Safety Initiatives Could Suffer Under Trump's Budget Proposal
Gilead Buys Its Third Priority Review Voucher, But Is The Mania Over?
Orphan Designation Requests To Get Slower Reviews





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts